A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1200 participants.

Also called NCT05394519

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,200 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05394519
  • EudraCT 2021-005121-24
  • jRCT jRCT2031220671
Other papers using this trial's data
  • Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes The New England journal of medicine, 2025-08-14 DOI, PubMed 40544432

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Austria, Canada, Germany, Hungary, India, Ireland, Japan, Malaysia, Poland, Puerto Rico, Thailand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05394519. Randomized; quadruple masking; primary purpose treatment. Start 2023-02-01 (actual); primary completion 2025-01-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Acronym
REDEFINE 2
Condition
Overweight
Condition
Obesity
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Cagrilintide
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo cagrilintide
Intervention (Drug)
Placebo semaglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05394519
Content hash
5d6df9db480c35a59edf046ec2bb65f960bd57603b93e6fc485a171286715128